HomeAgain, a widely-used pet microchipping and recovery service, has agreed to a $3.5 million class action settlement. Owned by Intervet and part of the Merck Animal Health company, HomeAgain faced allegations of misleading consumers into purchasing subscription plans they did not need for their pet microchips to function properly. The lawsuit did not question the safety or effectiveness of the microchips, but rather focused on the company's marketing and sales tactics, which were deemed as deceptive. The total settlement amount is estimated to be $3.5 million. Pet owners residing in specified states who paid for a HomeAgain premium service membership within certain time periods may qualify for a payout. The payout is estimated at $20.00 per claimant, although this could change depending on the number of valid and timely claim forms submitted. To claim, individuals must fill out a claim form online or by mail by the deadline of January 27, 2025. Proof of purchase may be required and claimants may need to verify their eligibility for payment. This lawsuit highlights the importance of transparent marketing in the pet care industry, particularly with services like pet microchipping which are often seen as essential for pet safety. It also serves as a reminder for consumers to fully understand the terms and conditions of any service subscription they sign up for. The case could potentially influence future industry practices and regulations to ensure clearer communication of service terms to consumers.